Observational studyNeurology2025
Implication for Clinical Trials From Longitudinal Tau-PET Accumulation Across Biological Alzheimer Disease Stages.
Observational study in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Hemispheric lateralization of Tau associations with visual and verbal memory in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical-biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data.Brain : a journal of neurology · 2026Article
- Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Visual versus quantitative tau-PET Braak staging in Alzheimer's disease using [European journal of nuclear medicine and molecular imaging · 2026Article
- Group-level versus individualized approaches for capturing tau PET changes and clinical progression in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Spatiotemporal dynamics of tau extent and load increase in Alzheimer's disease across four longitudinal cohorts.Nature aging · 2026Article
- APOE ε4 potentiates tau related reactive astrogliosis assessed by cerebrospinal fluid YKL40 in Alzheimer's disease.Communications medicine · 2025Article
- Rates of clinical progression according to biological Alzheimer's disease stages.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- From amyloid PET to plasma biomarkers: A multimodal imaging framework for early diagnosis and staging of Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesTau-PET is increasingly used in Alzheimer disease (AD) clinical trials, both for participant selection based on disease stage and as an outcome measure. However, the longitudinal patterns of tau accumulation according to AD stages remain unclear. We aimed to examine the patterns of tau-PET accumulation in different AD stages defined by the Alzheimer's Association Workgroup to inform trial design.
methodsThis was a retrospective analysis of data collected from participants in 2 longitudinal observational cohort studies: the Translational Biomarkers in Aging and Dementia (TRIAD) study from Montreal, Canada, and Alzheimer's Disease Neuroimaging Initiative (ADNI), a multisite study in North America. Amyloid-PET-positive participants were biologically staged as one of the following based on tau-PET uptake: A+T
resultsThe study included 542 participants (mean age: 67.9 ± 15.3 years; 56.3% female), comprising 321 non-AD controls and 221 individuals with AD. The baseline AD stage determined both the regional distribution and magnitude of tau accumulation. No significant accumulation occurred in A+T DISCUSSION: Stage-specific patterns of tau-PET change highlighted the importance of baseline biological AD staging for selecting outcome regions of interest. Statistical power analyses indicated that aligning outcome regions with disease stage reduced sample size estimates, suggesting potential gains in trial efficiency. While findings were consistent across 2 independent cohorts, differences in tracers and demographic composition represent key limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.